Nanoparticles of ZnO/Berberine complex contract COVID-19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity.

Doaa A GhareebSamar R SalehMohamed G SeadawyMohammed S NofalShaymaa A AbdulmalekSalma F HassanShaimaa M KhedrMiral G AbdElwahabAhmed A SobhyAli Saber Ali Abdel-HamidAbdelrahman Mohamed YassinAlshimaa A Abd ElmoneamAliaa A MasoudMohamed M Y KaddahSally A El-ZahabyAbdulaziz Mohsen Al-MahallawiAlaa M El-GharbawyAhmed ZakiInas K SeifMarwa Y KenawyMagdy AminKhaled AmerMaha Adel El Demellawy

Published in: Journal of pharmaceutical investigation (2021)

The ZnO/BER complex can be accounted as promising anti-COVID 19 candidate because it inhibited the virus entry, replication, and assembly. Furthermore, it could be used to treat a second bacterial infection that took place in hospitalized COVID 19 patients. Moreover, ZnO/BER complex was found to eliminate the toxicity of long-term administration of HCQ in vivo.

Keyphrases

sars cov
coronavirus disease
room temperature
quantum dots
reduced graphene oxide
oxidative stress
respiratory syndrome coronavirus
light emitting
oxide nanoparticles